Stemedica Cell Technologies, Inc.
COVID-19 / Acute Respiratory Distress Syndrome (ARDS) Services
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. This is a novel (or new) coronavirus that has not previously been seen in humans which has a wide range of symptoms reported with certain patients experiencing shortness of breath or difficulty breathing.
Most popular related searches
COVID 19
lung injury
stem cell
coronavirus disease
respiratory disease
clinical trial
respiratory distress
breath difficulty
breathing difficulty
coronavirus
Stemedica is initiating a multisite FDA-approved clinical trial to study the use of mesenchymal stem cells for severe lung injury from COVID-19 or other pneumonia titled A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in patients with Severe Lung Injury due to COVID-19 or Other Infectious Pathogens.